Clinical trial · Observational
Survivin and Fibulin-3 in Benign and Malignant Respiratory Diseases
Circulating and Local Expression Levels of Survivin and Fibulin-3 in Benign and Malignant Respiratory Diseases
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Purpose: Survivin is a common member of the inhibitors of the apoptosis protein (IAP) family with a dual role in promoting cell proliferation and preventing apoptosis. Fibulin-3, a matrix glycoprotein, was recently presented as a promising novel biomarker for malignant pleural mesothelioma. The aim of this study was to validate the expression levels of survivin and fibulin-3 in benign and malignant respiratory diseases. Patients and methods: The study included 73 patients, with various benign and malignant respiratory diseases. For validation of the data, a control group including 20 healthy subjects was chosen. The clinical and radiological assessments of the included individuals were done. The serum survivin and fibulin-3 levels were measured using ELISA assays kits, while their local expressions in the lung and pleura were assessed using western blot analysis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bronchial Neoplasm Benign | Lung Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ELISA assays and Westren blot analysis of survivin and fibulin-3 expression | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (5)
- label
- Group A
- description
- 21 patients with lung cancer
- interventionNames
- Diagnostic Test: ELISA assays and Westren blot analysis of survivin and fibulin-3 expression
- label
- Group B
- description
- 21 patients with various benign lung diseases
- interventionNames
- Diagnostic Test: ELISA assays and Westren blot analysis of survivin and fibulin-3 expression
- label
- Group C
- description
- Healthy controls
- interventionNames
- Diagnostic Test: ELISA assays and Westren blot analysis of survivin and fibulin-3 expression
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 35 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * any patients with Benign or Malignant Respiratory Diseases and agree to included in the study Exclusion Criteria: * Patients with renal failure, hepatic failure, severe cardiopulmonary compromise, coagulopathy or hemodynamically unstable were excluded
References
Publications (0)
Data not yet available